Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical TrialZOLOPA, Andrew R; BERGER, Daniel S; LAMPIRIS, Harry et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 814-822, issn 0022-1899, 9 p.Article

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients : 48-week results of a phase lib trialCOHEN, Calvin J; BERGER, Daniel S; MACK, Rebecca et al.AIDS (London). 2009, Vol 23, Num 3, pp 423-426, issn 0269-9370, 4 p.Article

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. CommentaryKURITZKES, Daniel R; GALLANT, Joel E; SHAEFER, Mark S et al.The Journal of infectious diseases. 2005, Vol 192, Num 11, pp 1867-1868, issn 0022-1899, 12 p.Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLENNOX, Jeffrey L; DEJESUS, Edwin; BARNARD, Richard J. O et al.Lancet (British edition). 2009, Vol 374, Num 9692, pp 796-806, issn 0140-6736, 11 p.Article